ELISA Kit for Interferon Alpha (IFNa)

7.8-500pg/mL

The minimum detectable dose of this kit is typically less than 3.0pg/mL

3h

This assay has high sensitivity and excellent specificity for detection of Interferon Alpha (IFNa).
No significant cross-reactivity or interference between Interferon Alpha (IFNa) and analogues was observed.

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Interferon Alpha (IFNa). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Interferon Alpha (IFNa). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Interferon Alpha (IFNa), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Interferon Alpha (IFNa) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

The cathelicidins LL-37 and rCRAMP are associated with pathogenic events of arthritis in humans and rats; Experimental rat model for alcohol-induced osteonecrosis of the femoral head; Andrographolide exerts anti-hepatitis C virus activity by up-regulating haeme oxygenase-1 via the p38 MAPK/Nrf2 pathway in human hepatoma cells; siRNA Targeting the 2A pro Genomic Region Prevents Enterovirus 71 Replication In Vitro; Sulforaphane Suppresses Hepatitis C Virus Replication by Up-ReCavia (Guinea pig )lating Heme Oxygenase-1 Expressionthrough PI3K/Nrf2 Pathway.; Host miR-146a promotes replication of human cytomegalovirus by suppressing type I IFN response in MRC-5 cells; MicroRNA-548j inhibits type I interferon production by targeting ZBTB11 in patients with chronic hepatitis B; Fucoidan from Fucus vesiculosus suppresses hepatitis B virus replication by enhancing extracellular signal-regulated Kinase activation.; Toll-like receptor 9 ligands increase type I interferon induced B-cell activating factor expression in chronic rhinosinusitis with nasal polyposis; Role of Toll‐like receptor 9 signaling on activation of nasal polyp–derived fibroblasts and its association with nasal polypogenesis; Collagen triple helix repeat containing-1: a novel biomarker associated with disease activity in Systemic lupus erythematosus; Scavenger receptor A impairs interferon response to HBV infection by limiting TRAF 3 ubiquitination through recruiting OTUB 1;